YIDU TECH (02158) has successfully completed the ownership registration of the tinnitus and hearing loss traditional Chinese medicine dataset.

Recently, the tinnitus and hearing loss traditional Chinese medicine (TCM) specialized disease dataset, developed with the support of leading domestic AI medical company YIDU TECH (02158), officially obtained the data ownership registration certificate in cooperation with the Third Affiliated Hospital of Zhejiang Chinese Medical University. This achievement provides a reference practical sample for the assetization of TCM specialized disease data and also confirms the effectiveness of YIDU TECH's data governance and standardized dataset construction capabilities in the TCM context. The diagnostic dimensions of TCM clinical data are diverse, with fragmented treatment records and mixed multimodal information, making standardized governance significantly more challenging than for ordinary Western medicine diseases. Since 2025, YIDU TECH has deeply cooperated with the Third Affiliated Hospital of Zhejiang Chinese Medical University to jointly build an integrated platform for clinical research, simultaneously focusing on three major specialized disease areas, and constructing a standardized specialized disease database, with tinnitus and hearing loss as the key focus. This database systematically integrates full-course information including TCM differential diagnosis classification, treatment methods, acupuncture therapy, modern hearing detection, and long-term follow-up, thus structuring and preserving the original diagnostic data. The project advances along a clear path of "specialized disease database construction - screening and processing - high-quality data integration - ownership confirmation." Based on the specialized disease clinical data accumulated by the hospital, YIDU TECH has provided professional data governance technical capabilities for processing the original medical records, including data cleaning and anonymization, standardized annotation, and quality assessment verification. The result is a high-quality dataset that is complete in fields, standardized in annotations, and research-grade reusable, meeting compliance circulation standards. It took about a month from the initiation of the special data processing to the completion of data ownership registration, which validates YIDU TECH's mature data governance and efficient delivery capabilities. The stable and efficient production of high-quality datasets relies on a systematic technical capability as its foundational support. With over a decade of deep cultivation in the field of medical data governance, YIDU TECH has established a mature "high-quality dataset solution based on specialized disease databases," featuring core standards such as traceability, high reliability, standardization, computability, and support for AI training and validation. Under strict adherence to data security and privacy protection regulations, the produced datasets can support clinical decision-making, scientific research innovation, drug development, and other diverse scenarios. As of March 31, 2026, YIDU TECH's independently developed "AI Medical Brain" YiduCore has authorized processing and analyzing nearly 9 billion medical records, covering over 12,000 medical institutions, and has supported the production of standardized datasets in more than 20 specialized disease areas. It has collaborated with domain experts to publish several dataset monographs such as the "Leukemia Standard Dataset" and the "Colorectal Cancer Standard Dataset," covering major disease areas including oncology, hematology, respiratory, and cardiovascular diseases. In terms of data compliance circulation, the company has produced multiple high-quality datasets in collaboration with several hospitals, which have completed ownership registration, forming a mature and replicable paradigm for high-quality dataset construction. YIDU TECH has also formed a deep foundation in the digitalization of TCM, with comprehensive data governance capabilities closely aligned with TCM business logic, supporting multiple TCM institutions in realizing clinical data value extraction. Currently, the company has co-built a research data center with Jiangsu Provincial Hospital of Traditional Chinese Medicine, focusing on key diseases to conduct clinical efficacy evaluation research compliant with TCM theoretical characteristics and international evidence-based norms; it collaborates with the Ningbo Provincial and Ministerial Key Laboratory of Kidney Essence Deficiency Syndrome to facilitate the transformation of research achievements in TCM preparations and the development of new TCM drugs, forming a full-scenario digital service capability that covers specialized disease database construction, real-world studies, and support for TCM innovation research and development. In the future, YIDU TECH will continue to expand the construction of high-quality datasets for advantageous TCM disease types, using safe and compliant data elements as a foundation to empower evidence-based TCM medical research, intelligent-assisted diagnosis and treatment development, innovative chronic disease management models, and other diverse scenarios, promoting the deep integration of traditional Chinese medicine and modern digital technology, helping medical institutions unlock the value of data assets, and injecting digital momentum into the inheritance, innovation of TCM, and the construction of a healthy China.